Low bedtime doses of H2-receptor antagonists for acute treatment of duodenal ulcer
- PMID: 2568246
- DOI: 10.1007/BF01536371
Low bedtime doses of H2-receptor antagonists for acute treatment of duodenal ulcer
Abstract
Twenty-four-hour intragastric acidity was measured continuously over five separate occasions in 15 patients with healed duodenal ulcers. They were randomized to receive either placebo, cimetidine 800 mg, ranitidine 150 mg, famotidine 20 mg, or nizatidine 150 mg, given at 2200 hr in double-blind fashion. All H2-receptor blockers were more effective than placebo in suppressing both circadian (P less than 0.05-P less than 0.01) and nocturnal (P less than 0.002) gastric acidity, while there was no significant differences between the effects of the four active drugs in the same time periods. The percentage of nocturnal acid inhibition (2300-0800 hr) over placebo in terms of H+ values was virtually 100% with all active treatments. The effect on daytime (0800-1700 hr) and evening (1700-2300 hr) acidity of both placebo and the four H2-receptor antagonists was similar. Therefore, in the above doses H2-receptor blockers guarantee overnight anacidity to a similar degree and cause the physiological buffering of daily meals on gastric acidity to be fully exploited. Furthermore, the reducing effect of daily meals on drug action can be prevented. Since strong acid suppression strictly confined to the nocturnal period has been shown to be closely correlated with the highest ulcer healing rates, it is suggested that single low bedtime doses of H2-receptor antagonist should be evaluated in the acute treatment of duodenal ulcer.
Similar articles
-
Comparison of the effects of placebo, ranitidine, famotidine and nizatidine on intragastric acidity by means of continuous pH recording.Digestion. 1989;42(1):1-6. doi: 10.1159/000199818. Digestion. 1989. PMID: 2568299 Clinical Trial.
-
Overnight comparable anacidity by standard large and half-single bedtime doses of H2 antagonists in duodenal ulcer patients: a clinical pharmacological study.Am J Gastroenterol. 1988 Sep;83(9):917-22. Am J Gastroenterol. 1988. PMID: 2901220 Clinical Trial.
-
Continuous intragastric pH monitoring: a real progress in the assessment of antisecretory drugs.Ital J Gastroenterol. 1990;22 Suppl 2:20-3. Ital J Gastroenterol. 1990. PMID: 1983412 Clinical Trial.
-
Acid secretion and acid suppression in pathogenesis and healing of peptic ulcer disease.Hepatogastroenterology. 1990 Jul;37 Suppl 1:18-28. Hepatogastroenterology. 1990. PMID: 1976583 Review.
-
Stress ulceration in the intensive care unit: use of H2-receptor antagonists.Aliment Pharmacol Ther. 1991;5 Suppl 1:111-9. doi: 10.1111/j.1365-2036.1991.tb00754.x. Aliment Pharmacol Ther. 1991. PMID: 1679669 Review.
Cited by
-
Indications for 24-hour gastric pH monitoring with single and multiple probes in clinical research and practice.Dig Dis Sci. 1992 Dec;37(12):1793-801. doi: 10.1007/BF01308070. Dig Dis Sci. 1992. PMID: 1473426
-
Comparison of low-dose antacids, cimetidine, and placebo on 24-hour intragastric acidity in healthy volunteers.Dig Dis Sci. 1992 Dec;37(12):1810-4. doi: 10.1007/BF01308072. Dig Dis Sci. 1992. PMID: 1473428 Clinical Trial.
-
Antisecretory effects of three omeprazole regimens for maintenance treatment in duodenal ulcer.Dig Dis Sci. 1994 Jul;39(7):1473-82. doi: 10.1007/BF02088051. Dig Dis Sci. 1994. PMID: 8026259 Clinical Trial.